Compare Davita Inc (DVA) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Microchip Technology Inc. — how do they compare? Davita Inc trades at $178.34 (market cap $11.72B), while Microchip Technology Inc. trades at $81.63 (market cap $44.20B). The key difference: Microchip Technology Inc. is far larger — about 3.8× Davita Inc's market cap, and Microchip Technology Inc. pays a 2.24% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | MCHP | |
|---|---|---|
Market Cap | $11.72B | $44.20B |
Sector | Health | Technology |
52-Week High | $240.96 | $102.97 |
52-Week Low | $103.87 | $49.02 |
Enterprise Value | $24.44B | $49.32B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Microchip Technology (MCHP) trades at $84.69, up 13.89% in 24 hours, reflecting strong momentum. The stock is in a bullish technical trend, with recent earnings beats and robust data center revenue growth of 98% last quarter. Analyst consensus is strongly bullish with a $104 price target. However, valuation ratios like a P/E of 124.54 are elevated, and 2025 net income was negative, posing fundamental concerns despite a recovery forecast for 2026.
Outlook is positive driven by AI and data center demand, but high valuation and past profitability volatility are risks. The stock offers growth exposure amid analyst optimism, yet investors should weigh premium pricing against execution risks in a competitive semiconductor market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
